Inno Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Inno Pharma
Largest movements
- Cash +€870
up €870 (+825.5%), from €105 to €975
mainly Other debts (+€1,700)
- Other debts +€1,700
up €1,700 (+113.3%), from €1,500 to €3,200
- Profit (loss) carried forward -€830
down €830 (-20.1%), from -€4,124 to -€4,955
- Other operating charges -€51
down €51 (-8.0%), from €635 to €585
- Financial charges +€30
up €30 (+20.0%), from €150 to €180
- Gross operating margin -€2
down €2 (-3.0%), from -€64 to -€66
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €376 | €1,245 | +€870 | +231.5% |
| Current assets | 29/58 | €376 | €1,245 | +€870 | +231.5% |
| Amounts receivable within one year | 40/41 | €270 | €270 | = | 0.0% |
| Other amounts receivable | 41 | €270 | €270 | = | 0.0% |
| Cash at bank and in hand | 54/58 | €105 | €975 | +€870 | +825.5% |
| Total equity and liabilities | 10/49 | €376 | €1,245 | +€870 | +231.5% |
| Equity | 10/15 | -€1,124 | -€1,955 | -€830 | -73.9% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€4,124 | -€4,955 | -€830 | -20.1% |
| Amounts payable | 17/49 | €1,500 | €3,200 | +€1,700 | +113.3% |
| Amounts payable within one year | 42/48 | €1,500 | €3,200 | +€1,700 | +113.3% |
| Other amounts payable | 47/48 | €1,500 | €3,200 | +€1,700 | +113.3% |
| Other operating charges | 640/8 | €635 | €585 | -€51 | -8.0% |
| Gross operating margin | 9900 | -€64 | -€66 | -€2 | -3.0% |
| Operating profit (loss) | 9901 | -€699 | -€650 | +€49 | +7.0% |
| Financial charges | 65/66B | €150 | €180 | +€30 | +20.0% |
| Recurring financial charges | 65 | €150 | €180 | +€30 | +20.0% |
| Profit (loss) for the period before taxes | 9903 | -€849 | -€830 | +€19 | +2.2% |
| Profit (loss) for the period | 9904 | -€849 | -€830 | +€19 | +2.2% |
| Profit (loss) for the period to be appropriated | 9905 | -€849 | -€830 | +€19 | +2.2% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 12 October 2026 via checked.be.